Hoth Therapeutics, Inc. (HOTH): Price and Financial Metrics

Hoth Therapeutics, Inc. (HOTH): $1.22

0.05 (-3.94%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add HOTH to Watchlist
Sign Up

HOTH Price/Volume Stats

Current price $1.22 52-week high $4.30
Prev. close $1.27 52-week low $0.99
Day low $1.22 Volume 28,100
Day high $1.31 Avg. volume 438,361
50-day MA $1.34 Dividend yield N/A
200-day MA $1.66 Market Cap 5.37M

HOTH Stock Price Chart Interactive Chart >


Hoth Therapeutics, Inc. (HOTH) Company Bio


Hoth Therapeutics, Inc. is a development stage biopharmaceutical company, which engages in the provision and development of therapeutic platform. The company focuses on the patients suffering from conditions such as atopic dermatitis, also known as eczema. It offers BioLexa Platform, a proprietary, patented, drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern in May 2017 and is headquartered in New York, NY.


HOTH Latest News Stream


Event/Time News Detail
Loading, please wait...

HOTH Latest Social Stream


Loading social stream, please wait...

View Full HOTH Social Stream

Latest HOTH News From Around the Web

Below are the latest news stories about HOTH THERAPEUTICS INC that investors may wish to consider to help them evaluate HOTH as an investment opportunity.

Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.

Yahoo | December 27, 2023

Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Hoth also recently completed its Pre-IND meeting with FDA in November.

Yahoo | December 5, 2023

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses provided by the FDA Nonmalignant Hematology Division of Regulatory Operations for Cardiology, Hematology, Endocrinology, and Nephrology.

Yahoo | November 14, 2023

Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie, Chief Executive Officer, is scheduled to present at the NobleCon 19th Annual Emerging Growth Investor Conference in Boca Raton, FL.

Yahoo | November 10, 2023

Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases.

Yahoo | October 5, 2023

Read More 'HOTH' Stories Here

HOTH Price Returns

1-mo 5.17%
3-mo -3.94%
6-mo -10.29%
1-year -40.49%
3-year -96.91%
5-year -99.08%
YTD -15.28%
2023 -81.54%
2022 -52.72%
2021 -72.16%
2020 -61.71%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!